What are the limitations of the adrenal incidentaloma malignancy risk?

While the adrenal incidentaloma malignancy risk is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the adrenal incidentaloma malignancy risk to ensure safe bedside use and optimal diagnostic accuracy.

How does the adrenal incidentaloma malignancy risk compare to other Endocrinology scores?

The adrenal incidentaloma malignancy risk is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the adrenal incidentaloma malignancy risk free to use?

Yes. OpiCalc provides the adrenal incidentaloma malignancy risk completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

Adrenal incidentaloma malignancy risk | Endocrinology Calculator

CLINICAL REFERENCE

CLINICAL INSIGHT

When to Use

Newly discovered adrenal mass (incidentaloma).
Determining the need for surgical excision vs imaging surveillance.
Evaluating unenhanced CT features of adrenal lesions.

CLINICAL INSIGHT

How it Works

Imaging Characteristics (Unenhanced CT)

Hounsfield Units (HU)	Size	Malignancy Risk	Recommendation
≤ 10 HU	Any	Near 0% (Lipid-rich adenoma)	No further imaging needed
11 - 20 HU	< 4 cm	Low	Repeat imaging in 6-12 months or consider washout protocol
> 20 HU	< 4 cm	Moderate	CT washout protocol or MRI chemical shift
Any (>10 HU)	≥ 4 cm	High	Surgical consultation (Adrenalectomy)

CLINICAL INSIGHT

Practical Pearls

CT Washout Protocol

If HU > 10, proceed to unenhanced CT with contrast washout (15-min delayed). Absolute Washout > 60% OR Relative Washout > 40% strongly suggests benign lipid-poor adenoma.

Pheochromocytoma Warning

NEVER biopsy an adrenal mass without ruling out a pheochromocytoma biochemically first. Biopsy of a pheo can cause a fatal hypertensive crisis.

CLINICAL INSIGHT

Next Steps

Metastasis vs Primary

If patient has a history of extra-adrenal malignancy (lung, breast, kidney, melanoma), any adrenal mass is a metastasis until proven otherwise.
Bilateral masses increase the suspicion for metastasis, congenital adrenal hyperplasia, or infiltrative diseases (TB, histoplasmosis).

CLINICAL INSIGHT

Evidence Base

Guidelines

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors

Fassnacht M, et al.Eur J Endocrinol2016

When to Use

When to Use

How it Works

Imaging Characteristics (Unenhanced CT)

Practical Pearls

CT Washout Protocol

Pheochromocytoma Warning

Next Steps

Metastasis vs Primary

Evidence Base

Guidelines

Adrenal Incidentaloma Malignancy Risk

When to Use

When to Use

How it Works

Imaging Characteristics (Unenhanced CT)

Practical Pearls

CT Washout Protocol

Pheochromocytoma Warning

Next Steps

Metastasis vs Primary

Evidence Base

Guidelines

Adrenal Incidentaloma Malignancy Risk

Clinical Evidence and Methodology

When to Use

When to Use

How it Works

Imaging Characteristics (Unenhanced CT)

Practical Pearls

CT Washout Protocol

Pheochromocytoma Warning

Next Steps

Metastasis vs Primary

Evidence Base

Guidelines

Adrenal Incidentaloma Malignancy Risk

Clinical Evidence and Methodology

When to Use

When to Use

How it Works

Imaging Characteristics (Unenhanced CT)

Practical Pearls

CT Washout Protocol

Pheochromocytoma Warning

Next Steps

Metastasis vs Primary

Evidence Base

Guidelines

Adrenal Incidentaloma Malignancy Risk